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Summary
We identified two large French-Canadian families seg-
regating a familial partial epilepsy syndrome with var-
iable foci (FPEVF) characterized by mostly nocturnal
seizures arising from frontal, temporal, and occasionally
occipital epileptic foci. There is no evidence for struc-
tural brain damage or permanent neurological dysfunc-
tion. The syndrome is inherited as an autosomal dom-
inant trait with incomplete penetrance. We mapped the
disease locus to a 3.8-cM interval on chromosome
22q11-q12, between markers D22S1144 and D22S685.
Using the most conservative diagnostic scheme, themax-
imum cumulative LOD score was 6.53 at recombination
fraction (v) 0 with D22S689. The LOD score in the
larger family was 5.34 at with the same marker.v = 0
The two families share an identical linked haplotype for
10 cM, including the candidate interval, indicating a
recent founder effect. A severe phenotype in one of the
probands may be caused by homozygosity for the caus-
ative mutation, as suggested by extensive homozygosity
for the linked haplotype and a bilineal family history of
epilepsy. An Australian family with a similar phenotype
was not found to link to chromosome 22, indicating
genetic heterogeneity of FPEVF.
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Introduction
Idiopathic epilepsies may be partial or generalized and
show specific, often age-related, clinical and electroen-
cephalographic (EEG) features. Three types of idiopathic
partial (localization-related) epilepsy were recognized by
the Commission on Classification and Terminology of
the International League Against Epilepsy (1989): be-
nign childhood epilepsy with centrotemporal spikes,
childhood epilepsy with occipital spikes, and primary
reading epilepsy. More recently, an increasing number
of idiopathic partial epilepsies has been described and
subjected to intensive genetic investigation (Berkovic and
Scheffer 1997b). These syndromes include: autosomal
dominant nocturnal frontal lobe epilepsy (ADNFLE
[MIM 600513]) (Scheffer et al. 1994, 1995a), familial
temporal lobe epilepsy (FTLE) (Berkovic et al. 1996;
Andermann et al. 1997; Cendes et al. 1998), rolandic
epilepsy with speech dyspraxia (MIM 601085) (Scheffer
et al. 1995b), and familial partial epilepsy with variable
foci (FPEVF) (Scheffer et al. 1998). Several idiopathic
partial epilepsies show familial aggregation compatible
with the effect of a major Mendelian gene (Berkovic and
Scheffer 1997a), and in some, single-gene inheritance
was confirmed by linkage studies and positional cloning.
Mutations of the gene encoding the a-4 subunit of the
neuronal nicotinic acetylcholine receptor on chromo-
some 20q were found to cause ADNFLE in an Australian
(Phillips et al. 1995; Steinlein et al. 1995) and in a Nor-
wegian family (Steinlein et al. 1997). A second locus for
ADNFLE was more recently mapped to chromosome
15q, in the region where a cluster of genes encoding
subunits of the neuronal nicotinic acetylcholine receptor
is localized (Phillips et al. 1998). Because most families
with ADNFLE do not show linkage either to chromo-
some 20 or to chromosome 15, at least one other, un-
mapped, locus must exist for this syndrome (Phillips et
al. 1998). A gene determining a specific form of FTLE
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called “partial epilepsy with auditory symptoms” (MIM
600512) has been mapped to chromosome 10q (Ottman
et al. 1995). Preliminary results suggest linkage of
FPEVF to chromosome 2 in an Australian family (Schef-
fer et al. 1998).
In an effort to contribute to the clinical and genetic
definition of idiopathic partial epilepsy, we searched for
families showing familial aggregation of idiopathic par-
tial epilepsy. Here we report a linkage study of two large
French-Canadian families sharing common ancestors
that segregate a form of FPEVF as an autosomal dom-
inant trait with reduced penetrance.
Patients and Methods
Ascertainment and Genealogy
The probands of families 22 and 14 were studied at
the Montreal Neurological Hospital (MNH). Family
trees were constructed, extending the pedigrees as many
generations back as possible. The Australian FPEVF
family was previously described by Scheffer et al. (1998).
Probands and Family Histories
We obtained seizure histories from all putatively af-
fected and unaffected individuals, as well as from mar-
ried-in spouses. We corroborated the histories by inter-
viewing close relatives and reviewing medical records.
Interviews were conducted at the MNH and during sev-
eral field trips to the Quebec City region. To be classified
as affected for linkage analysis, the records had to in-
clude at least a neurological and general examination,
routine electroencephalogram (EEG), and a CT and/or
magnetic resonance imaging (MRI) scan to exclude
structural brain lesions. Four hospitalized patients, in-
cluding the probands of families 22 and 14, also had a
neuropsychological examination, sleep EEG, 24-hour
video telemetry monitoring, volumetric MRI, and either
functional MRI, magnetic resonance spectroscopy, or
positron emission tomography for confirmation of epi-
leptic foci.
The study protocol was approved by the institutional
ethics committees, and informed consent was obtained
from each individual or from a parent or guardian in
the case of minors.
Family 22: proband and family history.—The proband
is a 13-year-old boy from Saint-Raymond (Quebec, Can-
ada), the second of two siblings. The parents are not
known to be consanguineous. He was admitted for in-
vestigation of intractable epilepsy, which started at age
5 years. The seizures are mainly nocturnal and involve
deep breathing, followed by pelvic movements, turning
of the head to the right, and tonic flexion of the left arm
and leg. Neurological and general examinations were
normal. Video telemetry monitoring revealed bilateral
frontal onset of seizures with right-sided predominance,
followed by spread to the right temporal area. Interictal
spikes and sharp waves were observed only in the right
frontotemporal region. MRI, including volumetric MRI,
revealed no structural lesions or asymmetries. A diag-
nosis of right frontal epilepsy without structural abnor-
malities was made.
He had a family history of epilepsy. Among 119 family
members (not including married-in spouses) in five gen-
erations, 25 individuals had seizures, including his father
and paternal grandfather. Some relatives of his mother
also had epilepsy, but no detailed investigations of this
branch of the family have been carried out to date. Sleep
disorders in childhood, three adults with positional ver-
tigo, and three adults with paranoid schizophrenia were
also identified in this family.
Family 14: proband and family history.—The proband
is a 16-year-old male from Levis (Quebec, Canada), the
youngest of three siblings whose parents are not known
to be consanguineous. Seizures started at age 5 years
with “absence” episodes. Over the years, he developed
mainly nocturnal attacks occurring 5–10 times per
month, characterized by tonic movements of the left
upper extremity and, occasionally, of the left lower ex-
tremity and hemiface. Neurological and general exam-
inations were normal. Video telemetry monitoring re-
vealed an apparently generalized onset for clinical and
electrographic seizures. An active interictal epileptic ab-
normality was recorded from the right frontotemporal
convexity, often with simultaneous reflection in mesial
temporal structures. MRI showed that the left hippo-
campus was smaller than the right. A diagnosis of right
frontal epilepsy was made.
Family history was positive for epilepsy. Though most
family members now live in Levis, some of their ances-
tors moved there from Saint-Raymond, where family 22
also originates. Of 79 family members (not including the
married-in spouses), 11 in three generations had seizures,
including the proband’s father. Nonepileptic neurolog-
ical or psychiatric disorders include: three family mem-
bers with episodes of de´ja` vu and/or jamais vu but no
overt seizures, eight family members who have classical
migraine with visual auras, three children with sleep dis-
orders, one child with febrile convulsions, and an adult
with paranoid schizophrenia.
Definition of the Epileptic Syndrome
Clinical data were obtained for 34 individuals with a
history of seizures, 24 from family 22 and 10 from fam-
ily 14. All initial histories and EEGs were reported by
one of four experienced epileptologists from Quebec
City (R.D., G.P., S.V., and P.L.) and then reviewed and
classified by three epileptologists from MNH (F.A., F.D.,
and S.F.B.). Consensus on affection status and locali-

Figure 1 Pedigrees of two French-Canadian families segregating FPEVF. Only individuals indicated with blackened symbols were considered as affected in the analysis to establish linkage and
then were used to identify the critical interval. Chromosome 22q11-q12 marker data are indicated below each typed individual. The disease-associated haplotype is boxed. In 22 individuals (panel
A), two deduced paternal recombinations that define the centromeric boundary of the candidate region can be detected: one recombination occurred between D22S1144 and D22S1163 in II:1, the
other between D22S1154 and D22S1144 in II:15. A paternal recombination between D22S685 and D22S280 occurred in III:16 and defines the telomeric boundary of the candidate interval. Note
the homozygosity of the proband of family 22 (IV:30) for all but two distal markers. For distances between the markers, refer to figure 2. Inferred haplotypes are in parentheses.
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zation of the epileptic focus was reached for each in-
dividual before the analysis of marker data. An effort
was made to identify a set of core clinical characteristics
that define the specific genetic syndrome, in order to
exclude from primary mapping all cases whose pheno-
type or medical history suggests the possibility of a dif-
ferent etiology. Twenty-three individuals (16 from family
22 and seven from family 14) were found to share
enough common clinical features to define a specific id-
iopathic partial epilepsy syndrome. DNA samples were
available from all but one (from family 22). These in-
dividuals were classified as affected in the subsequent
linkage analysis and are indicated with blackened sym-
bols infigure 1. Their phenotypes include: (1) recurring
partial seizures originating from different cortical areas;
(2) absence of any detectable pathological lesion(s); (3)
exclusively or predominantly nocturnal seizures; (4) var-
iable age of onset, with two peaks around 5 and 25
years; (5) relatively inactive EEGs; (6) in most cases, a
good response to therapy with antiepileptic medications
(Xiong et al. 1998). The most peculiar characteristic of
the syndrome is the variable localization of the epileptic
focus in different family members, which prompted us
to classify it as a form of FPEVF. Not all brain regions
seem to be equally susceptible, because almost all pa-
tients have their epileptic focus in the frontal or temporal
lobe, as indicated by the clinical characteristics of the
seizures and, in four subjects (the two probands, one
individual with frontal seizures, and one individual with
temporal seizures), by video telemetry. Only one indi-
vidual from family 22 (III:21 infig. 1A) has an occipital
focus in the context of an otherwise compatible clinical
picture. Because of this unusual presentation, he was
classified as unknown for linkage analysis. Unknown
status was also given to three subjects with symptomatic
epilepsy (II:11 infig. 1A, who has post-stroke seizures;
III:60 infig. 1A, who had occipital trauma before the
onset of occipital epilepsy; II:7 infig. 1B, who has post-
traumatic epilepsy), as well as to two subjects who have
idiopathic or cryptogenic epilepsy with distinct clinical
features (II:14 infig. 1B, who has temporal lobe epilepsy
with onset at age 1 year and diurnal seizures; an indi-
vidual from family 22 not shown infig. 1, who has typ-
ical benign childhood occipital epilepsy as described by
Panayiotopoulos [1989]), and to two subjects who may
have FPEVF by history, but whose records are insuffi-
cient (III:48 and IV:5 infig. 1A). The proband of family
22 (IV:30 infig. 1A) was also given unknown status,
because his severe refractory epilepsy raised the suspi-
cion of an undetected symptomatic origin and because
both parents reported a family history of epilepsy, a pos-
sible confusing factor for linkage analysis. Clinical and
EEG data were reviewed for seven individuals with ep-
isodic nonepileptic disorders such as classical migraine,
isolated de´ja` vu, and parasomnias in childhood, and for
14 asymptomatic subjects (including married-in
spouses). None had EEG abnormalities, and they were
all considered unaffected. This diagnostic scheme (di-
agnostic scheme 1) was used for the purpose of gene
mapping by linkage analysis.
In both families, the mode of inheritance of this idio-
pathic epileptic disorder appears to be autosomal dom-
inant, as indicated by vertical and male-to-male trans-
mission. Incomplete penetrance is suggested by the
absence of a history of seizures in some obligate carrier
individuals.
Genotyping and Molecular Methods
Genomic DNA was isolated by phenol-chloroform ex-
traction (Gustafson et al. 1987). Manual screening of
chromosomes 15–22 was performed with markers from
the CHLC human screening set/Weber version 8, mostly
tetra- and trinucleotide repeats. DNA fragments were
amplified by PCR in a total volume of 12.5 ml with
standard PCR buffer, a 0.2-mM concentration of each
primer (one end-labeled with g-32P-ATP used at 0.5 #
106 cpm/reaction), a 0.125 mM concentration of each
dNTP, 40 ng of DNA, and 0.5 U of Taq polymerase
(Pharmacia). Thirty-three temperature cycles, consisting
of 40 s either at 94C, 55C, and 72C (tetra- and tri-
nucleotide repeats) or at 94C and 55C (dinucleotide
repeats), were used for PCR amplification. The amplified
fragments were separated on 6%, 5%, or 4% polyacryl-
amide gels, depending on their size, in denaturing con-
ditions. Radioactive PCR products were detected by
autoradiography after electrophoresis. Part of the ge-
nomewide scan was performed using a screening set of
fluorescently labeled markers (screening set-3, SS3),
mostly tetra- and trinucleotide repeats, which were an-
alyzed on an automatic ABI PRISM 377 sequencer (PE
Biosystems) equipped with appropriate software.
The TrC polymorphism (position 836 of the mRNA
sequence) in the ADORA2 gene (Genbank accession
number U40771) was genotyped to resolve a contradic-
tory localization of this gene in the GB4 and G3 radi-
ation hybrid maps in GeneMap 98. Primers F (5′-TGG
CAG TGA CGG AGA GCA GGT-3′) and R (5′-AGG
AAG GGG CAA ACT CCA TGA-3′) from the second
exon of the gene were used to amplify a DNA fragment
containing the polymorphism. Genomic DNA was am-
plified by PCR in the conditions as described above for
tetranucleotide markers, except that both primers were
radioactively labeled and the annealing temperature was
60C. Polymorphic variants were detected by single-
strand DNA polymorphism (SSCP) analysis on 7% poly-
acrylamide gel, as described elsewhere (Zietkiewicz et
al. 1992).
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Linkage Analysis
We initially genotyped the families with markers from
chromosomal regions harboring loci known to be linked
to idiopathic partial epilepsy syndromes, particularly the
suggested FPEVF locus on chromosome 2 (Scheffer et
al. 1998), the ADNFLE loci on chromosomes 20 (Phil-
lips et al. 1995) and 15 (Phillips et al. 1998), and the
FTLE with auditory symptoms locus on chromosome 10
(Ottman et al. 1995). These loci were excluded by re-
combination and highly negative LOD scores (data not
shown). We then proceeded to a whole-genome scan.
Preliminary simulation analysis using the SLINK pro-
gram (Weeks et al. 1990) indicated that family 22 had
enough power to establish linkage when utilizing diag-
nostic scheme 1 and analysis parameters as described
below. After linkage was established, markers from the
linked region were tested on all available members of
families 22 and 14 and on the Australian FPEVF family.
Linkage analysis was performed using the maximum-
likelihood, parametric approach (via LOD score). Two-
point LOD scores were calculated using the MLINK
program (Lathrop et al. 1985), version 5.1. Diagnostic
scheme 1 was initially used to define affected individuals
for linkage analysis. After linkage was established, LOD
scores were recalculated according to diagnostic schemes
2 and 3. Diagnostic scheme 2 considers as affected all
individuals with idiopathic partial epilepsy, even if only
by history, and regardless of severity and localization of
the focus. Subjects with symptomatic epilepsy or with
distinct clinical features are still excluded. This scheme
adds to the affected group the subject with occipital
seizures (III:21 infig. 1A), two individuals with history
of partial epilepsy and no evidence of brain disease, but
incomplete records (III:48 and IV:5 infig. 1A), and the
proband of family 22 (IV:30 infig. 1A). In diagnostic
scheme 3, every individual with epilepsy was considered
affected. This scheme adds to the affected group the
subjects with symptomatic epilepsy (II:11 and III:60 in-
fig. 1A and II:7 infig. 1B) and the individual with early-
onset, diurnal temporal lobe seizures (II:14 infig. 1B). A
single autosomal dominant model with 50% penetrance
was utilized in all cases, as suggested by inspec-
tion of the pedigrees. In both pedigrees, almost all in-
dividuals were typed, and the genotypes of a few de-
ceased or unavailable persons could be unequivocally
reconstructed by analyzing spouses and offspring (as
shown infig. 1). Alleles were numbered as follows: the
longest variant was assigned number 1, and all the
shorter ones were numbered by adding the number of
repeats by which they differed from allele 1. Alleles were
assigned equal frequency in the LOD-score analysis.
Haplotypes were constructed using the Cyrillic program
(Cherwell Scientific) version 2, using the most parsi-
monious phase by tracing segregation of alleles in
families.
Results
Linkage Analysis
Before significant evidence of linkage with D22S685
was found, 111 markers were tested (table 1). Next, we
used 22 additional polymorphic markers on the long
arm of chromosome 22, selected from the Ge´ne´thon map
(Dib et al. 1996) and from the Genetic Location Da-
tabase to finely map the disease locus. Their physical
order was obtained from the Sanger Centre physical map
of chromosome 22. All markers are positioned in contig
22 in this map.Table 1 shows LOD scores obtained in
families 22 and 14, with markers listed in cenrtel order
according to the Sanger Centre map. With the most con-
servative diagnostic scheme (scheme 1), we obtained the
highest cumulative LOD score of 6.53 for D22S689 at
recombination fraction (v) 0 (table 1). This marker gen-
erated a LOD score of 5.34 in family 22. Seven addi-
tional markers generated maximum LOD scores 13 in
family 22: D22S275, D22S1150, D22S1176, and
D22S273 at , D22S280 and D22S1162 at ,v = 0 v = .05
D22S1144 at (table 1). A candidate interval wasv = .10
defined by analysis of recombination events (fig. 1).
Flanking markers are D22S1144 on the centromeric
side, as shown by the recombinant haplotype of II:1 and
his affected descendants III:1 and IV:1 (fig. 1A), and
D22S685 on the telomeric side, as shown by the
crossing-over that occurred in III:16 (fig. 1A). Affected
individuals in family 22 and family 14, with the excep-
tion of those showing recombinations involving the
more centromeric markers, share the same alleles in a
region centromeric to D22S1175 and extending 10
cM, to D22S421 (figure 2). According to the Ge´ne´thon
map, in which D22S685 does not appear, the genetic
distance between D22S1144 and D22S280, which is
next to D22S685 in the Sanger Centre map, is 3.8 cM.
The physical size of the D22S1144–D22S685 interval is
∼4 Mb, according to the Sanger Centre map.
The adenosine receptor type 2 gene (ADORA2), a
possible candidate gene whose physical location was un-
certain because of contrasting results in the analysis of
two radiation hybrid sets (GB4 and G3), was excluded
from the candidate region. Several recombinants with
the disease locus were identified by analysis of a poly-
morphism in the coding sequence of this gene, placing
ADORA2 centromeric to the candidate interval.
LOD scores were recalculated according to diagnostic
schemes 2 and 3 for the 12 linked markers shown intable
1 (seven in the critical interval). The application of di-
agnostic scheme 2 resulted in increased maximum LOD
scores, with no changes in the recombination fractions
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Table 1
LOD Scores between FPEVF and Chromosome 22 Markers in Two French-Canadian Families
MARKER,
DIAGNOSTIC SCHEME,
AND FAMILY
LOD SCORE AT v =a
Zmax vmax0 .05 .10 .15 .20 .25 .30
D22S1154:
1:
22 3.01 .13 .43 .68 .77 .76 .67 .77 .20
14 1.78 1.73 1.62 1.48 1.30 1.09 .86 1.78 0
Overall 1.24 1.60 2.05 2.15 2.07 1.85 1.53 2.15 .15
2:
22 .13 1.99 2.18 2.14 1.99 1.75 1.43 2.18 .10
14 1.78 1.73 1.62 1.48 1.30 1.09 .86 1.78 0
Overall 1.90 3.72 3.80 3.62 3.29 2.84 2.29 3.80 .10
3:
22 .61 1.04 1.50 1.64 1.60 1.46 1.23 1.64 .15
14 1.98 .16 .31 .52 .61 .61 .55 .61 .20
Overall 2.59 .88 1.81 2.16 2.21 2.07 1.78 2.21 .20
D22S1144:
1:
22 .57 3.69 3.77 3.57 3.24 2.81 2.30 3.77 .10
14 1.78 1.73 1.62 1.48 1.30 1.09 .86 1.78 0
Overall 1.21 5.42 5.39 5.05 4.54 3.90 3.16 5.42 .05
2:
22 2.07 5.32 5.11 4.72 4.21 3.61 2.94 5.32 .05
14 1.78 1.73 1.62 1.48 1.30 1.09 .86 1.78 0
Overall 3.85 7.05 6.74 6.19 5.51 4.70 3.80 7.05 .05
3:
22 1.97 4.37 4.43 4.21 3.82 3.32 2.72 4.43 .10
14 1.95 .16 .31 .52 .61 .61 .54 .61 .20
Overall .01 4.20 4.74 4.73 4.43 3.92 3.27 4.74 .10
D22S1163:
1:
22 2.90 2.66 2.40 2.12 1.82 1.50 1.16 2.90 0
14 1.08 .94 .78 .63 .48 .36 .25 1.08 0
Overall 3.98 3.59 3.18 2.74 2.30 1.85 1.41 3.98 0
2:
22 3.88 3.52 3.15 2.76 2.35 1.93 1.50 3.88 0
14 1.08 .94 .78 .63 .48 .36 .25 1.08 0
Overall 4.97 4.46 3.93 3.39 2.84 2.29 1.75 4.97 0
3:
22 1.98 2.57 2.47 2.25 1.96 1.64 1.28 2.57 .05
14 .82 .01 .13 .18 .19 .18 .16 .19 .20
Overall 1.16 2.56 2.60 2.43 2.15 1.82 1.44 2.60 .10
D22S275:
1:
22 3.32 3.90 3.77 3.48 3.10 2.65 2.14 3.90 0
14 1.78 1.73 1.62 1.48 1.30 1.09 .86 1.78 0
Overall 5.10 5.63 5.39 4.96 4.40 3.74 3.00 5.63 0
2:
22 6.46 6.05 5.58 5.04 4.43 3.77 3.05 6.46 0
14 1.78 1.73 1.62 1.48 1.30 1.09 .86 1.78 0
Overall 8.24 7.78 7.20 6.51 5.73 4.86 3.91 8.24 0
3:
22 4.56 5.10 4.90 4.52 4.04 3.48 2.83 5.10 .05
14 1.98 .16 .31 .52 .61 .61 .55 .61 .25
Overall 2.58 4.94 5.21 5.05 4.65 4.09 3.38 5.21 .10
D22S1150:
1:
22 3.18 2.96 2.71 2.43 2.13 1.80 1.45 3.18 0
14 1.18 1.17 1.12 1.02 .90 .74 .57 1.18 0
Overall 4.36 4.13 3.82 3.45 3.03 2.55 2.02 4.36 0
(continued)
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Table 1 (Continued)
MARKER,
DIAGNOSTIC SCHEME,
AND FAMILY
LOD SCORE AT v =a
Zmax vmax0 .05 .10 .15 .20 .25 .30
2:
22 3.73 3.46 3.16 2.84 2.49 2.11 1.70 3.73 0
14 1.18 1.17 1.12 1.02 .90 .74 .57 1.18 0
Overall 4.91 4.63 4.28 3.86 3.38 2.85 2.27 4.91 0
3:
22 3.73 3.46 3.16 2.84 2.49 2.11 1.70 3.73 0
14 2.58 .72 .20 .07 .21 .26 .26 .26 .25
Overall 1.15 2.74 2.97 2.91 2.70 2.37 1.96 2.97 .10
D22S689:
1:
22 5.34 5.10 4.73 4.29 3.77 3.20 2.58 5.34 0
14 1.18 1.17 1.12 1.02 .90 .74 .57 1.18 0
Overall 6.53 6.28 5.85 5.31 4.67 3.95 3.15 6.53 0
2:
22 7.42 6.86 6.25 5.59 4.89 4.13 3.32 7.42 0
14 1.18 1.17 1.12 1.02 .90 .74 .57 1.18 0
Overall 8.60 8.03 7.36 6.61 5.78 4.87 3.89 8.60 0
3:
22 5.52 5.90 5.57 5.08 4.49 3.84 3.11 5.90 .05
14 2.58 .72 .20 .07 .21 .26 .26 .26 .25
Overall 2.94 5.19 5.37 5.15 4.70 4.10 3.37 5.37 .10
D22S1176:
1:
22 3.15 2.93 2.69 2.41 2.12 1.79 1.44 3.15 0
14 .30 .28 .25 .23 .20 .17 .14 .30 0
Overall 3.45 3.21 2.94 2.64 2.32 1.97 1.59 3.45 0
2:
22 3.15 3.02 2.83 2.59 2.31 1.99 1.63 3.15 0
14 .30 .28 .25 .23 .20 .17 .14 .30 0
Overall 3.45 3.29 3.08 2.82 2.51 2.16 1.77 3.45 0
3:
22 3.15 3.02 2.83 2.59 2.31 1.99 1.63 3.15 0
14 .30 .28 .25 .23 .20 .17 .14 .30 0
Overall 3.45 3.29 3.08 2.82 2.51 2.16 1.77 3.45 0
D22S273:
1:
22 4.42 4.23 3.92 3.53 3.09 2.60 2.06 4.42 0
14 1.39 1.30 1.19 1.07 .93 .78 .61 1.39 0
Overall 5.80 5.53 5.11 4.60 4.02 3.38 2.67 5.80 0
2:
22 6.43 5.91 5.34 4.75 4.11 3.44 2.73 6.43 0
14 1.39 1.30 1.19 1.07 .93 .78 .61 1.39 0
Overall 7.81 7.21 6.54 5.82 5.04 4.22 3.34 7.81 0
3:
22 4.52 4.95 4.67 4.24 3.72 3.15 2.51 4.95 .05
14 1.39 1.30 1.19 1.07 .93 .78 .61 1.39 0
Overall 5.91 6.25 5.86 5.31 4.65 3.92 3.12 6.25 .05
D22S1175:
1:
22 .59 .52 .46 .39 .32 .26 .20 .59 0
14 .05 .08 .10 .10 .09 .08 .06 .10 .10
Overall .64 .60 .55 .49 .41 .34 .26 .64 0
2:
22 .84 .75 .66 .57 .48 .40 .31 .84 0
14 .05 .08 .10 .10 .09 .08 .06 .10 .10
Overall .89 .83 .76 .67 .57 .47 .36 .89 0
(continued)
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Table 1 (Continued)
MARKER,
DIAGNOSTIC SCHEME,
AND FAMILY
LOD SCORE AT v =a
Zmax vmax0 .05 .10 .15 .20 .25 .30
3:
22 .84 .75 .66 .56 .47 .38 .28 .84 0
14 .30 .29 .27 .23 .19 .14 .09 .09 .30
Overall .54 .46 .39 .33 .28 .24 .19 .54 0
D22S685:
1:
22 .14 .93 1.04 1.03 .95 .83 .69 1.04 .10
14 1.48 1.45 1.37 1.25 1.10 .92 .71 1.48 0
Overall 1.62 2.38 2.41 2.28 2.05 1.75 1.40 2.41 .10
2:
22 .51 1.32 1.42 1.38 1.27 1.10 .90 1.42 .10
14 1.48 1.45 1.37 1.25 1.10 .92 .71 1.48 0
Overall 1.99 2.77 2.79 2.63 2.36 2.02 1.61 2.79 .10
3:
22 1.34 .37 .74 .87 .88 .81 .68 .88 .20
14 .13 .77 .94 .97 .91 .80 .64 .97 .15
Overall 1.47 1.14 1.69 1.84 1.79 1.60 1.32 1.84 .15
D22S280:
1:
22 3.47 4.03 3.87 3.56 3.16 2.69 2.17 4.03 .05
14 1.78 1.73 1.62 1.48 1.30 1.09 .86 1.78 0
Overall 5.25 5.75 5.49 5.04 4.46 3.79 3.03 5.75 .05
2:
22 3.97 4.54 4.39 4.06 3.64 3.12 2.54 4.54 .05
14 1.78 1.73 1.62 1.48 1.30 1.09 .86 1.78 0
Overall 5.75 6.27 6.01 5.54 4.94 4.22 3.40 6.27 .05
3:
22 2.14 3.59 3.71 3.55 3.25 2.83 2.32 3.71 .10
14 .17 1.05 1.20 1.20 1.11 .97 .79 1.20 .10
Overall 2.31 4.64 4.91 4.75 4.36 3.80 3.11 4.91 .10
D22S1162:
1:
22 2.67 3.48 3.47 3.28 2.96 2.56 2.08 3.48 .05
14 1.18 1.15 1.07 .96 .82 .66 .49 1.18 0
Overall 3.85 4.63 4.55 4.24 3.79 3.22 2.58 4.63 .05
2:
22 5.51 5.89 5.56 5.07 4.48 3.83 3.10 5.89 .05
14 1.18 1.15 1.07 .96 .82 .66 .49 1.18 0
Overall 6.69 7.04 6.63 6.03 5.31 4.49 3.59 7.04 .05
3:
22 3.67 4.94 4.88 4.56 4.09 3.53 2.88 4.94 .05
14 .43 .47 .65 .68 .64 .54 .42 .68 .15
Overall 3.24 5.41 5.53 5.24 4.73 4.07 3.30 5.53 .10
a Some entries do not sum to totals shown, because of rounding error.
at which they occurred. As only individuals from family
22 were added to the affected group when using this
scheme, LOD scores changed only for this family. The
highest LOD score for family 22 reached 7.42 and was
obtained with D22S689 at . The corresponding cu-v = 0
mulative LOD score for both families was 8.60. Com-
pared to diagnostic scheme 1, family 22 generated a
LOD score 13 with one more marker, D22S1163, at
. When diagnostic scheme 3 was used, all maximumv = 0
LOD scores for family 14 decreased and were obtained
at higher recombination fractions. Maximum LOD
scores also decreased for family 22 when compared with
diagnostic scheme 2, but they were usually higher than
with diagnostic scheme 1, despite a general increase in
the recombination fractions at which they were ob-
tained. This behavior is readily explained by looking at
marker haplotypes. All subjects added to the affected
group when applying diagnostic scheme 2 carry the dis-
ease-associated haplotype. The application of diagnostic
scheme 3 added one more individual with the disease-
associated haplotype to the affected group, III:60 from
family 22 (fig. 1A), as well as three subjects without the
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Figure 2 Disease haplotypes in families 22 and 14. The order of markers is based on the physical map of contig 22 in the Sanger Centre
map, genetic distances (sex-averaged) are according to the Ge´ne´thon map (Dib et al. 1996). F22 designates the disease haplotype in family 22,
F22* the maternal haplotype of the proband of family 22. F14 designates the disease haplotype in family 14. Shared haplotype portions are
gray. Markers within the candidate interval defined by recombination analysis are in bold. The 3.8-cM candidate region is marked by an arrow.
disease-associated haplotype, one from family 22 (II:11
infig. 1A), and two from family 14 (II:7 and II:14 infig.
1B).
Since multiple diagnostic schemes were used, a cor-
rection for multiple testing should be introduced when
evaluating the significance of the results. Accordingly,
LOD scores should be decreased by log10 3, this being
the number of tested models. The resulting values for
the highest LOD scores, obtained with diagnostic
scheme 2, are 8.12 (cumulative) and 6.94 (family 22
only), both well above the cutoff of 3.3 proposed by
Lander and Kruglyak (1995) for LOD-score analyses in
humans. The corresponding genomewide P values are
1.2 # 107 and 1.7 # 105, respectively (Lander and
Kruglyak 1995).
Genotype-Phenotype Correlations
We genotyped all available members of families 22
and 14 with chromosome 22 markers to estimate the
phenotypic spectrum of the partial epilepsy gene seg-
regating in these families (fig. 1). In generation II (mean
age 71 years, range 61–80), only 27% (3/11) of subjects
carrying the linked marker haplotype had epilepsy com-
patible with the FPEVF syndrome. A history of epilepsy
may be underreported in this generation, both for cul-
tural reasons and because a few nocturnal partial sei-
zures at a relatively young age might have been over-
looked or been interpreted as sleep disturbance. In
generation III, whose mean age is 43 years (range
32–56), 76% (16/21) of the subjects carrying the linked
marker haplotype had epilepsy compatible with FPEVF.
This generation carries fewer cultural constraints against
reporting a history of epilepsy and seizures were expe-
rienced more recently. The individual with idiopathic
occipital seizures in family 22 (III:21 infig. 1A), whose
affection status was considered unknown for the map-
ping study because of the unusual location of the epi-
leptic focus, was found to carry the linked haplotype. A
second subject with occipital seizures from the same ped-
igree (III:60 infig. 1A), who had occipital head trauma,
was also found to carry the disease-associated haplotype.
Additional individuals excluded from the mapping study
because of uncertainties in the diagnosis, but who had
a history highly suggestive of FPEVF and were consid-
ered as affected in diagnostic scheme 2, were also found
to carry the linked haplotype. Conversely, two individ-
uals with possible symptomatic epilepsy, post-traumatic
(II:7 infig. 1B) or post-stroke (II:11,fig. 1A), and a sub-
ject with a distinct syndrome of temporal lobe epilepsy
(II:14 infig. 1B) were found not to carry the linked hap-
lotype. Most subjects with nonepileptic episodic disor-
ders or with isolated episodes of de´ja` vu also do not
carry the linked haplotype.
The proband of family 22, who was excluded from
the mapping study because of the severity and refrac-
toriness to treatment of his epilepsy and because of a
history of epilepsy in both parents’ families, was found
to be homozygous for all markers contained within the
7.8-cM interval between D22S1154 and D22S1175,
which includes the entire critical region centromeric to
D22S685. Considering the marker allele frequencies, this
event is expected to occur by chance with a probability
of less than 106. Furthermore, his maternal haplotype
matches the haplotype segregating with the disease in
family 14 for 21 cM, from D22S1154 to D22S445,
the most telomeric marker we tested (fig. 2), suggesting
a close relationship between family 14 and maternal rel-
atives of the proband of family 22, also from the town
of Saint-Raymond. We propose that this individual may
be homozygous for the causative mutation, resulting in
a more severe phenotype. Several affected individuals are
homozygous for two or three contiguous markers in the
candidate interval. Such limited homozygosity very
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likely occurred by chance, as none of these individuals
has a severe phenotype or evidence of bilineal inheritance
of epilepsy.
Discussion
We identified a specific epilepsy syndrome which ap-
pears to be determined by a single major gene and is
characterized by predominantly nocturnal partial sei-
zures originating from variable brain areas in the absence
of detectable structural abnormalities. We called the syn-
drome familial partial epilepsy with variable foci
(FPEVF), the term introduced by Scheffer et al. (1998)
to classify an Australian family with similar phenotype.
Rigorous and critical analysis of the clinical data was
essential to achieve this result. Epilepsy is common, so
the simple finding of multiple cases in a pedigree does
not necessarily indicate that a specific genetic syndrome
is segregating in the family. Furthermore, some affected
individuals may have epilepsy of a different kind. The
identification of a set of clinical features that characterize
the syndrome, despite the variability of clinical presen-
tations, was therefore a necessary prerequisite for the
linkage study.
We chose the maximum-likelihood parametric method
for linkage analysis—the most powerful method, for
Mendelian disorders—for several reasons. First, inspec-
tion of the pedigrees strongly suggested that a single
major autosomal dominant mutation with reduced pen-
etrance was responsible for the epilepsy phenotype. Sec-
ond, single-gene inheritance had previously been dem-
onstrated for other idiopathic partial epilepsies. Third,
the LOD-score method can be the most powerful as long
as an appropriate model for the locus being tested is
utilized, even if the “real” model involves several genes
(Greenberg et al. 1998).
As for marker loci, the assumption of equal allele fre-
quencies facilitated the calculations and is highly un-
likely to have led to false positive results, because there
were very few untyped individuals, and because their
haplotypes could always be unequivocally inferred. In
addition, results were highly consistent for all markers
in the linked region.
Our linkage study provides strong evidence that a sin-
gle major gene on chromosome 22 causes FPEVF in two
French-Canadian pedigrees (14 and 22). Only after link-
age was firmly established, by use of a conservative di-
agnostic scheme, did we use two more diagnostic
schemes to define affected individuals for LOD-score
analysis. Assuming that the model that generates the
highest LOD score is the best approximation to the
“real” characteristics of the trait under study, diagnostic
scheme 2 seems to provide the best definition of the
phenotype among those tested. Accordingly, FPEVF is
characterized by nocturnal frontal, temporal, or occip-
ital epilepsy of variable severity that is most often—but
not always—responsive to treatment. Since the approach
of maximizing the maximum LOD score with respect to
the clinical parameters (Clarget-Darpoux et al. 1986;
Greenberg 1990; Hodge and Elston 1994) carries an
increased risk of false positive results, significance levels
should be reevaluated after adjusting for the multiple
models that were tested (Clerget-Darpoux et al. 1986).
Thanks to the size of the families we studied, our results
remain highly significant even after this correction.
The linked haplotype in the two families is the same
across a region of 10 cM, pointing to a recent founder
effect, probably coinciding with the establishment in the
first half of the 19th century of the town of Saint-Ray-
mond, from which both pedigrees originate. Interest-
ingly, one individual, the proband of family 22, is ho-
mozygous for the linked haplotype, and epilepsy was
present in relatives of both parents. This individual is
highly likely to be homozygous for the causative mu-
tation and is severely affected with intractable epilepsy.
Obviously , successful mapping of the major gene de-
termining FPEVF in these families does not exclude the
possibility that other genes influence the phenotype. This
is, in fact, quite likely, when the observed reduced pen-
etrance and variability of the phenotype are considered.
It should come as no surprise that this idiopathic partial
epilepsy syndrome—like many disorders caused by a sin-
gle major gene with Mendelian inheritance—has a com-
plex, multifactorial etiology that determines the specific
phenotype of each gene carrier, in which modifier genes,
acquired factors, and chance may all play a role.
The Australian FPEVF family described in Scheffer et
al. (1998), which previously provided suggestive linkage
for chromosome 2, was also tested for linkage to chro-
mosome 22. This family was not found to be linked to
chromosome 22q11-q12. Clinical findings that could
differentiate it from our families 22 and 14 include: (1)
a wider range of ages at onset, varying from 10 mo to
44 years and possibly to 55 years in one deceased in-
dividual; (2) predominantly diurnal seizures; (3) more
interictal EEG activity even in individuals with frontal
seizures. Overall, the genetic background of FPEVF is
distinct from that of other idiopathic partial epilepsies:
FPEVF is genetically, and probably clinically, hetero-
geneous.
The candidate interval on chromosome 22 covers a
genetic distance of !4 cM between D22S685 and
D22S1144 and has a physical size of ∼4 Mb. The region
is entirely within the Sanger Centre contig 22, and fin-
ished or unfinished sequence is available for most of it.
Known genes mapping in this interval include those en-
coding (in cenrtel order): the X-box binding protein 1
(XBP1); the growth-arrest protein GAR22; the ras-re-
lated protein RRP22; an oncogene involved in Ewing
sarcoma (EWS); b-adaptin (ADTBL); the neurofilament
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heavy polypeptide (NEFH); the NF2 protein, merlin; the
leukemia inhibitory factor (LIF); oncostatin M
(ONCM); transcobalamin II (TCN2); smoothelin
(SMTN); the brain-specific h isoform of the 14.3.3 pro-
tein, also known as tyrosine/ tryptophan mono-oxygen-
ase activating protein (YWMAP); the sodium-glucose
transporter 1 (SGLT1); the immunoglobulin l chain
(IGL); and the synaptic vesicle protein synapsin III.
We excluded the adenosine-receptor type 2 gene
(ADORA2) from the candidate region because of mul-
tiple recombinations, detected by analysis of a coding-
sequence polymorphism. The genes encoding synapsin
III and the brain-specific h isoform of the 14.3.3 protein
(YWMAP) are appealing candidates for FPEVF. After
synapsins I and II, synapsin III is the most recently iden-
tified member of a gene family encoding proteins asso-
ciated with synaptic vesicles that regulate neurotrans-
mitter release (Kao et al. 1998). Knockout mice for
synapsin I and synapsin II, as well as mice with the
double knockout, are viable and fertile and have no
structural brain abnormality but develop epilepsy (Ro-
sahl et al. 1995). The severity of epilepsy in these knock-
out mice is proportional to the number of disrupted
synapsin genes (Rosahl et al. 1995), suggesting paral-
lelism with the observation of a severe phenotype in the
proband of family 22, possibly homozygous for the mu-
tation. The synapsin III gene is localized at the telomeric
end of the candidate interval, with the flanking markers
D22S280 and D22S685 lying in a very large intron be-
tween exons 5 and 6, according to the Sanger Centre
map. Despite this peripheral location, it is not excluded
because of the possibilities of intragenic recombination
and of a recombination hot spot in this large intron.
The YWMAP gene is entirely within the candidate
region, between D22S273 and D22S1175. It encodes a
brain-specific protein with roles in the control of intra-
cellular signaling and neurotransmitter release. Alter-
natively, a still-unidentified gene may be responsible. A
large number of expressed sequence tags (ESTs) and of
putative exons have been localized in the region, and
their analysis will certainly speed the process of new gene
identification.
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